FRESH TRACKS THERAPEUTICS IN (FRTX)
US10802T2042 - Common Stock
Taking everything into account, FRTX scores 2 out of 10 in our fundamental rating. FRTX was compared to 586 industry peers in the Biotechnology industry. While FRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. FRTX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year FRTX has reported negative net income.
In the past year FRTX has reported a negative cash flow from operations.
FRTX had negative earnings in each of the past 5 years.
In the past 5 years FRTX always reported negative operating cash flow.
1.2 Ratios
FRTX's Return On Assets of -68.63% is on the low side compared to the rest of the industry. FRTX is outperformed by 67.28% of its industry peers.
The Return On Equity of FRTX (-82.48%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.63% | ||
| ROE | -82.48% | ||
| ROIC | N/A |
ROA(3y)-133.33%
ROA(5y)-101.24%
ROE(3y)-176.24%
ROE(5y)-148.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FRTX has been increased compared to 1 year ago.
FRTX has more shares outstanding than it did 5 years ago.
FRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -17.49, we must say that FRTX is in the distress zone and has some risk of bankruptcy.
FRTX has a Altman-Z score of -17.49. This is amonst the worse of the industry: FRTX underperforms 88.81% of its industry peers.
There is no outstanding debt for FRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.49 |
ROIC/WACCN/A
WACC10.98%
2.3 Liquidity
A Current Ratio of 6.19 indicates that FRTX has no problem at all paying its short term obligations.
FRTX has a Current ratio (6.19) which is in line with its industry peers.
A Quick Ratio of 6.19 indicates that FRTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.19, FRTX is in line with its industry, outperforming 59.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 68.84% over the past year.
The Revenue has grown by 101.00% in the past year. This is a very strong growth!
The Revenue for FRTX have been decreasing by -12.87% on average. This is quite bad
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q115.46%
Revenue 1Y (TTM)101%
Revenue growth 3Y-4.31%
Revenue growth 5Y-12.87%
Revenue growth Q2Q1520.41%
3.2 Future
The Earnings Per Share is expected to grow by 3.32% on average over the next years.
Based on estimates for the next years, FRTX will show a decrease in Revenue. The Revenue will decrease by -8.37% on average per year.
EPS Next Y5.44%
EPS Next 2Y3.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-58.02%
Revenue Next 2Y-8.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
FRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.32%
EPS Next 3YN/A
5. Dividend
5.1 Amount
FRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRESH TRACKS THERAPEUTICS IN
NASDAQ:FRTX (12/18/2023, 7:00:00 PM)
After market: 0.77 -0.02 (-2.53%)0.79
-0.02 (-2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.63% | ||
| ROE | -82.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.19 | ||
| Quick Ratio | 6.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)68.84%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)101%
Revenue growth 3Y-4.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y